BETRF Stock Chart & Stats
$0.04
$0.02(32.60%)
At close: 4:00 PM EST
$0.04
$0.02(32.60%)
Day’s Range― - ―
52-Week Range$0.03 - $0.12
Previous CloseN/A
Volume32.97K
Average Volume (3M)43.71K
Market Cap
$17.10M
Enterprise Value$11.41M
Total Cash (Recent Filing)$12.57K
Total Debt (Recent Filing)$905.00K
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding161,787,020
10 Day Avg. Volume49,808
30 Day Avg. Volume43,712
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.75
Price to Sales (P/S)0.00
P/FCF Ratio-11.66
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnOperating cash flow has materially improved (from ~-$2.0M in 2025 to ~-$0.6M TTM), reflecting sustained cost control. That durable reduction in cash burn extends runway, reduces near-term financing pressure and increases optionality to reach clinical milestones or secure partnerships.
Narrowing Net LossesNet losses have narrowed substantially over multiple years (from ~-$12.2M in 2022 to ~-$1.5M TTM), indicating ongoing operational discipline. Persistent improvement improves the company's ability to steward limited capital, reduce dilution per financing, and make development progress with fewer external interventions.
Focused CNS PipelineA concentrated strategy on neuropsychiatric and neurological therapeutics creates domain expertise and a clear clinical focus. That structural specialization increases odds of targeted licensing partnerships, aligns with durable unmet medical need in CNS, and sharpens go-to-market and development decisions.
Bears Say
No Reported RevenueThe company reports no commercial revenue and remains pre‑commercial, meaning operations depend on financing or milestone/licensing receipts. This structural lack of recurring revenue heightens dilution risk, constrains reinvestment capacity, and makes progress contingent on successful clinical or partner outcomes.
Negative Shareholder EquityDeeply negative shareholder equity (~-$9.8M TTM) reflects accumulated deficits and reduces financial flexibility. Negative equity can limit borrowing capacity, weaken negotiating leverage with partners or lenders, and increase the probability that future funding will be dilutive or come on less favorable terms.
Fragile Balance Sheet / Tiny AssetsThe company has a very small asset base (~$0.22M TTM) and minimal tangible resources, leaving little collateral for borrowing and limited capacity to scale operations. Even with lower nominal debt (~$0.9M TTM), the fragile capital structure creates ongoing refinancing and operational risk absent new non-dilutive funding.
BetterLife Pharma News
BETRF FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was $0.03 and its highest was $0.12 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is $17.10M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Sep 30, 2026 which is in 92 days.
How were BetterLife Pharma’s earnings last quarter?
Currently, no data Available
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 161,787,020 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in BETRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BetterLife Pharma
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.
Technical Analysis
COSCIENS Biopharma
―
PharmaTher Holdings Ltd
―
Marvel Biosciences Corp
―
Doseology Sciences
―
PharmAla Biotech Holdings, Inc.
―
Ownership Overview
28.21% Insiders
<0.01% Other Institutional Investors
71.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---